==== Front Intest ResIntest ResIRIntestinal Research1598-91002288-1956Korean Association for the Study of Intestinal Diseases 10.5217/ir.2018.16.3.358Focused Review: Colorectal CancerSerrated neoplasia pathway as an alternative route of colorectal cancer carcinogenesis Kim Soon Young Kim Tae Il Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.Correspondence to Tae Il Kim, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Tel: +82-2-2228-1965, Fax: +82-2-393-6884, taeilkim@yuhs.ac7 2018 27 7 2018 16 3 358 365 05 3 2018 28 5 2018 29 5 2018 © Copyright 2018. Korean Association for the Study of Intestinal Diseases.2018Korean Association for the Study of Intestinal DiseasesThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.In the past two decades, besides conventional adenoma pathway, a subset of colonic lesions, including hyperplastic polyps, sessile serrated adenoma/polyps, and traditional serrated adenomas have been suggested as precancerous lesions via the alternative serrated neoplasia pathway. Major molecular alterations of sessile serrated neoplasia include BRAF mutation, high CpG island methylator phenotype, and escape of cellular senescence and progression via methylation of tumor suppressor genes or mismatch repair genes. With increasing information of the morphologic and molecular features of serrated lesions, one major challenge is how to reflect this knowledge in clinical practice, such as pathologic and endoscopic diagnosis, and guidelines for treatment and surveillance. Serrated neoplasiaColorectal neoplasmCarcinogenesisHyperplastic polyp ==== Body INTRODUCTION Colorectal cancer (CRC) holds the third rank in cancer incidence and the major cause of cancer-related death in the world.1 In Asia, the incidence of CRC rapidly increased between 1998 and 2007, and CRC became the leading cause of cancer-related death.2 For two decades, conventional adenomas were considered the only precancerous lesions of CRC.3 However, other type of colonic lesions have been considered to have malignant potential which progress via the alternative serrated neoplasia pathway.456789 Circumstantial evidence has shown that the serrated neoplasia pathway contributes to the development of 15% to 30% of all CRCs.41011 The latest World Health Organization (WHO) guideline published in 2010 described sporadic serrated polyp lesions have a typical serrated (“saw-tooth” or stellate) architecture of the crypt lining epithelium. Sporadic serrated polyps are subdivided into sessile serrated adenoma/polyps (SSA/Ps), traditional serrated adenomas (TSAs), and hyperplastic polyps (HPs).12 Clinically, a large portion of post-colonoscopy interval cancers are suspected of developing from serrated polyps.13141516 The development of high resolution endoscopic equipment and an improvement of colonoscopy quality has enhanced recognition of serrated lesions, such as right-sided flat lesions with indiscrete margins.17 The purpose of this review is an overview of the clinicopathological and molecular features of alternative serrated pathway in colorectal carcinogenesis to promote better management and clinical outcomes. CLASSIFICATION OF SERRATED PRECURSORS 1. Hyperplastic Polyps HPs are the most prevalent (60%–75%) serrated lesions.1819 Twenty-five percent of the average risk individuals have 1 or more HPs, which are located in left side colon.18 HPs are generally equal to or smaller than 5 mm with a flat or sessile endoscopic feature.20 Histopathologic characteristics of HPs include elongated crypts with proliferation and serration of the upper crypts without cytological atypia.21 HPs can be subclassified on the basis of mucin type into microvesicular HPs (MVHPs), goblet-cell-rich HPs (GCHPs), and mucin-poor HPs (MPHPs).12 MVHP is the most common subtype, accounting for 60% of HPs.20 Histologically, MVHPs are characterized by columnar cells with lots of microvesicular mucin and stellate crypt openings.722 Because MVHPs commonly exhibit BRAF mutations (80%) and occasionally present increased CpG island methylation, 2324 especially in proximal lesions, they are considered precursors of SSA/Ps. When they are large and located in the right colon, it is difficult to distinguish MVHPs from SSA/Ps. GCHPs account for 30% of HPs252627 and have more rounded crypt openings than MVHPs, showing abundant mature goblet cells in the upper crypt with tendency of left-sided location in colon.2228 GCHPs are linked to KRAS mutations which are presented in approximately 50% of cases,2429 suggesting the possibility of progression to TSAs.30 MPHPs, the rarest form of HPs, lack goblet cells, and are considered a variant of MVHPs developed from reactive change with unknown clinical significance.31 2. Sessile Serrated Adenomas or Polyps SSA/Ps are comprised of 20% to 35% of colorectal serrated lesions.1819 SSA/Ps were first mentioned by Torlakovic et al.2232 in 1996, but before 2003, SSA/Ps were labeled HPs.6 Current SSA/Ps were defined by WHO classification.12 However, the terminology has remained controversial. Recently, the British Society of Gastroenterology suggested that it should be renamed to “sessile serrated lesions” because it shows neither cytologic dysplasia nor polypoid morphology.3334 The diagnosis of SSA/Ps has increased as our knowledge of this entity grows, both endoscopically and pathologically. 203536 However, the prevalence of SSA/Ps is thought to be underestimated, because there was some discrepancy between expected SSA/P detection rate and actual detection rate of 16% and 12%, respectively in patients with an average CRC risk.1837 In addition, SSA/Ps are most commonly located proximally, but 20% to 40% are also detected in the distal colon.1838 SSA/Ps are histopathologically characterized by patterns including irregular branching, dilation towards the base, and L-shaped or inverted T-shaped crypts (Fig. 1). The inverted crypts can be found below the muscularis mucosa, which is designated as displaced crypts or pseudoinvasion.1221 In addition, SSA/Ps can have cytologic dysplasia, which is more progressive form in adenoma carcinoma sequence.12 Previous studies reported the prevalence of SSA/Ps with dysplasia as 20% to 30% of entire SSA/Ps.1838 The median age of patients with SSA/Ps without dysplasia was 61 years, which with SSA/Ps with dysplasia was 66 years, and which with SSA/P with early cancer was 72 years. This increasing tendency of median age of prevalence indicates their serial progression.9 Meanwhile, the differentiation of SSA/P from MVHP is difficult, especially in small lesions.39 Therefore, a recent consensus recommended that a single characteristic crypt base is enough to diagnose SSA/P, and MVHPs larger than 10 mm should be considered equivalent to SSA/Ps for clinical or surveillance purposes.20 3. Traditional Serrated Adenomas TSAs, the rarest subtype of serrated lesions,181929 are usually pedunculated in shape, and located in the left colon and rectum (Fig. 1).204041 Histologic differentiation of TSAs from tubulovillous adenomas is more difficult than histologic differentiation of SSA/Ps.1221 TSAs are serrated and show villous or tubulovillous configuration that is composed of columnar cells with intensively and diffusely eosinophilic cytoplasm (Fig. 1).202142 Ectopic crypt foci is another important finding of TSAs, which are small aberrant crypts that develop horizontally without anchoring to the underlying muscularis mucosa.21 Cytologic dysplasia (90% low-grade and 10% high-grade) is also commonly presented in TSAs.1221 Filiform serrated adenoma is a rare, less aggressive variant form of TSAs that is characterized by thin and elongated projection lined by neoplastic epithelium.4344 SERRATED NEOPLASIA PATHWAY Three molecular pathways of CRC carcinogenesis have been established: (1) chromosomal instability (CIN); (2) microsatellite instability (MSI); and (3) CpG island methylator phenotype (CIMP), which is also referred to the serrated neoplasia pathway or epigenetic instability pathway. These pathways are related with each other in complex way in carcinogenesis, and the serrated neoplasia pathway is considered to be separated from traditional pathway (Fig. 2).42645 Hypermethylation of CpG islands on the promoter regions of tumor suppressor genes and subsequent silencing is common in CRC. For example, silencing of hMLH1 leads to mismatch repair (MMR) dysfunction, which results in sporadic MSI. This CIMP, was observed in 20% to 30% of CRC and is one of the major molecular characteristics of the serrated neoplasia pathway.4647 In a previous study, CIMP was detected in 11% of MVHPs and 40% of SSA/Ps.48 CIMP was found not only in serrated polyps, but also in histologically normal mucosa of patients with hyperplastic polyposis syndrome, which supports that CIMP is an important early step of the serrated pathway.495051 In addition, hypermethylation of hMLH1 gene, a DNA MMR gene, was detected in 40% of sporadic CIMP+ CRC. When it is inactivated by hypermethylation, high frequency MSI (MSI-high) is induced, and these lesions tend to develop additional mutations, including BAX, PTEN, MSH3, MSH6, and IGF2R.52 As a result of these mutations, rapid development of cytologic dysplasia and carcinomatous transformation may occur. Relatively rapid development of CRC by the serrated pathway is suggested in the literature, comparable with carcinogenesis in patients with Lynch syndrome.53 In addition, Bettington et al.54 reported 74.5% loss of hMLH1 in SSA/Ps containing dysplasia/carcinoma, showing its relationship with older age, female gender, proximal location, CIMP, and lack of aberrant p53. Prior to CIMP, a mutation in the BRAF proto-oncogene is the most pronounced key feature in the initial phase of the serrated neoplastic pathway (MSI high and/or CIMP high CRC), which activates the mitogen activated protein kinase (MAPK) cascade. This BRAF mutation results in uncontrolled cell proliferation, similar to KRAS mutation in adenomas. Incidence of BRAF mutation has been reported as 50% to 72% of MVHPs, 70% to 80% of SSA/Ps, and only 1% of tubular adenomas.2555 Because of the exclusive mutation between BRAF and KRAS, however, KRAS mutations were reported to have low prevalence in CIMP-high CRCs.56 Mutations of BRAF or KRAS activate cell proliferation, which is followed by cell senescence.57 If tumor suppressor genes are silenced, as with methylation of p16INK4a or p53 mutations, BRAF or KRAS-induced senescence can be avoided with progression of carcinogenesis.585960 Silencing by methylation of insulin-like growth factor binding protein 7 (IGFBP7), an important mediator of p53 induced senescence, also induces an escape from cell senescence.61 Furthermore, the Wnt signaling pathway, a major signaling pathway of CIN+ CRC, could be involved in the serrated neoplastic pathway. For example, some reports showed that aberrant β-catenin accumulation was detected in 0 out of 19 HPs and 9 out of 22 (41%) SSA/Ps.62 Another study reported aberrant β-catenin accumulation in 8 out of 27 (29%) SSA/Ps without dysplasia and 27 out of 27 (100%) SSA/Ps with dysplasia, suggesting that the Wnt pathway is involved in progression of SSA/Ps, rather than early change of SSA/Ps.56 The mechanism and role of the Wnt signaling in the serrated pathway is not well understood, but silencing by methylation of mutated in colorectal cancer gene (MMC), which correlates with BRAF mutation and CIMP, might have an important role because MMC suppress Wnt signaling via interactions with β-catenin.24 The molecular pathway of TSA development is not well understood. However, it is characterized by promoter hypermethylation and subsequent silencing of the methylguanine methyltransferase (MGMT), KRAS mutation, and CIMP low tumor.426364 ENDOSCOPIC DIAGNOSIS AND MANAGEMENT Clinically, serrated polyps are considered to be related with the development of interval CRCs. Therefore, endoscopic detection and complete removal is important.65 Endoscopic detection rates of SSA/Ps vary because these lesions are frequently flat and resemble folds of the proximal colon. Magnifying chromoendoscopy and narrow-band imaging (NBI) can facilitate distinction of serrated lesions, but it is not enough to differentiate between SSA/Ps and HPs.66 For detection and diagnosis, it is important to know the distinct features of SSA/Ps (Fig. 1). HPs are usually smaller than 5 mm, and have a pale color and a stellate type II Kudo pit pattern on chromoendoscopy or NBI.6768 The endoscopic features of SSA/Ps are sessile or flat morphology, pale color, indistinct borders with mucus capping, and rim of bubbles or debris.69707172 With NBI, a cloud-like surface, dark spots inside crypts, and type II-O or open Kudo pit pattern, which is wider and more rounded than type II pit pattern, are highly predictive of SSA/Ps.72 Meanwhile, TSAs show protuberant and/or pedunculated shape with a type IV pit pattern and a fern-like feature.7374 In addition, HPs and TSAs tend to locate in the distal part of colon, while SSA/Ps are more frequently observed in the proximal colon.9192975 There is no conclusive evidence-based guideline on management of serrated polyps, but new guidelines recommend that all serrated polyps should be endoscopically removed, except small and diminutive HPs in the rectosigmoid area. SSA/Ps are reported to have higher incomplete resection rates due to their flat shape and indiscrete borders.76 Chromoendoscopy contrast dye can be used to define the border of these lesions,630 and lifting of the lesion is helpful in identifying accurate margins. Therefore endoscopic mucosal resection is an appropriate method for endoscopic teatment.6 If the lesion is not suitable for endoscopic resection due to difficult location or huge size, segmental colectomy is advised.77 As for surveillance after removal of serrated polyp, U.S. Multi-Society Task Force recommended 5-year surveillance interval for SSA/Ps smaller than 10 mm without dysplasia,78 which is shorter than 10 years recommended by European Society of Gastrointestinal Endoscopy guideline.79 Most guidelines recommended 3-year interval for SSA/Ps equal or larger than 10 mm, SSA/Ps with dysplasia, and TSAs.787980 After piecemeal resection of large SSA/Ps, follow-up within 6 months is recommended, consistently. CONCLUSIONS In the past two decades, as our knowledge of the morphologic and molecular features and clinical meaning of serrated lesions increased, its detection and diagnosis rate has been improved. Now, we should consider about how to reflect this knowledge in clinical practice, such as pathologic and endoscopic diagnosis, and guidelines for treatment and surveillance. Further investigations about the molecular mechanisms, natural history, and management strategies are needed. FINANCIAL SUPPORT: The authors received no financial support for the research, authorship, and/or publication of this article. CONFLICT OF INTEREST: No potential conflict of interest relevant to this article was reported. AUTHOR CONTRIBUTION: Conceptualization, writing - review and editing, approval of final manuscript: Tae Il Kim. Writing - original draft: Soon Young Kim. Fig. 1 Endoscopic and histologic features of sessile serrated polyps and traditional serrated adenoma. Endoscopic appearance of sessile serrated adenoma (SSA) with white light endoscopy shows smooth and indistinct surface pattern covered with mucus (A). Chromoendoscopy after indigo carmine dye spraying in SSA shows clear boundaries and characteristic pit pattern (type II-O) (B, C). Microscopic features of SSA show irregular branching and T-shaped or L-shaped basal crypt (H&E, ×400) (D). Endoscopic appearance of traditional serrated adenoma (TSA) shows protruded polypoid shape with villous surface (E), and microscopic feature of TSA shows villous serration with dysplasia (H&E, ×40) (F). Fig. 2 Simplified models of the sessile and traditional serrated pathways. MVHP, microvesicular hyperplastic polyp; GCHP, goblet cell-rich hyperplastic polyp; IGFBT7, insulin-like growth factor-binding protein 7; SSA/P, sessile serrated adenoma/polyp; TSA, traditional serrated adenoma; TSG, tumor suppressor gene; hMLH1, human MutL homolog 1; MGMT, O-6-methylguanine-DNA methyltransferase; SSA/P-D, SSA/polyp with dysplasia; TSA-D, TSA with dysplasia; SAC, serrated adenocarcinoma; meth, methylation; MSS, microsatellite stable; CIMP-H, CpG island methylator phenotype-high; MSI, microsatellite instability; CIMP-L, CpG island methylator phenotype-low. ==== Refs 1 Siegel RL Miller KD Jemal A Cancer statistics, 2017 CA Cancer J Clin 2017 67 7 30 28055103 2 Tsoi KKF Hirai HW Chan FC Griffiths S Sung JJ predicted increases in incidence of colorectal cancer in developed and developing regions, in association with ageing populations Clin Gastroenterol Hepatol 2017 15 892 900 27720911 3 Muto T Bussey HJ Morson BC The evolution of cancer of the colon and rectum Cancer 1975 36 2251 2270 1203876 4 Snover DC Update on the serrated pathway to colorectal carcinoma Hum Pathol 2011 42 1 10 20869746 5 Boparai KS Dekker E Polak MM Musler AR van Eeden S van Noesel CJ A serrated colorectal cancer pathway predominates over the classic WNT pathway in patients with hyperplastic polyposis syndrome Am J Pathol 2011 178 2700 2707 21641392 6 East JE Saunders BP Jass JR Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management Gastroenterol Clin North Am 2008 37 25 46 18313538 7 Bettington M Walker N Clouston A Brown I Leggett B Whitehall V The serrated pathway to colorectal carcinoma: current concepts and challenges Histopathology 2013 62 367 386 23339363 8 Oono Y Fu K Nakamura H Progression of a sessile serrated adenoma to an early invasive cancer within 8 months Dig Dis Sci 2009 54 906 909 18688718 9 Lash RH Genta RM Schuler CM Sessile serrated adenomas: prevalence of dysplasia and carcinoma in 2139 patients J Clin Pathol 2010 63 681 686 20547691 10 Jass JR Classification of colorectal cancer based on correlation of clinical, morphological and molecular features Histopathology 2007 50 113 130 17204026 11 Toyota M Ahuja N Ohe-Toyota M Herman JG Baylin SB Issa JP CpG island methylator phenotype in colorectal cancer Proc Natl Acad Sci U S A 1999 96 8681 8686 10411935 12 Snover D Serrated polyps of the colon and rectum and serrated polyposis Bosman FT Carneiro F Hruban RH Theise ND WHO classification of tumours of the digestive system 4th ed Lyon IARC 2010 160 165 13 Burgess NG Tutticci NJ Pellise M Bourke MJ Sessile serrated adenomas/polyps with cytologic dysplasia: a triple threat for interval cancer Gastrointest Endosc 2014 80 307 310 24890425 14 Arain MA Sawhney M Sheikh S CIMP status of interval colon cancers: another piece to the puzzle Am J Gastroenterol 2010 105 1189 1195 20010923 15 le Clercq CM Sanduleanu S Interval colorectal cancers: what and why Curr Gastroenterol Rep 2014 16 375 24532192 16 Nishihara R Wu K Lochhead P Long-term colorectal-cancer incidence and mortality after lower endoscopy N Engl J Med 2013 369 1095 1105 24047059 17 Arthur JF Structure and significance of metaplastic nodules in the rectal mucosa J Clin Pathol 1968 21 735 743 5717544 18 Hazewinkel Y de Wijkerslooth TR Stoop EM Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy Endoscopy 2014 46 219 224 24254386 19 Carr NJ Mahajan H Tan KL Hawkins NJ Ward RL Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma J Clin Pathol 2009 62 516 518 19126563 20 Rex DK Ahnen DJ Baron JA Serrated lesions of the colorectum: review and recommendations from an expert panel Am J Gastroenterol 2012 107 1315 1329 22710576 21 Aust DE Baretton GB Members of the Working Group GI-Pathology of the German Society of Pathology Serrated polyps of the colon and rectum (hyperplastic polyps, sessile serrated adenomas, traditional serrated adenomas, and mixed polyps)-proposal for diagnostic criteria Virchows Arch 2010 457 291 297 20617338 22 Torlakovic E Skovlund E Snover DC Torlakovic G Nesland JM Morphologic reappraisal of serrated colorectal polyps Am J Surg Pathol 2003 27 65 81 12502929 23 O'Brien MJ Yang S Mack C Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points Am J Surg Pathol 2006 30 1491 1501 17122504 24 Burnett-Hartman AN Newcomb PA Phipps AI Colorectal endoscopy, advanced adenomas, and sessile serrated polyps: implications for proximal colon cancer Am J Gastroenterol 2012 107 1213 1219 22688851 25 Fernando WC Miranda MS Worthley DL The CIMP phenotype in BRAF mutant serrated polyps from a prospective colonoscopy patient cohort Gastroenterol Res Pract 2014 2014 374926 24812557 26 Leggett B Whitehall V Role of the serrated pathway in colorectal cancer pathogenesis Gastroenterology 2010 138 2088 2100 20420948 27 Rosty C Hewett DG Brown IS Leggett BA Whitehall VL Serrated polyps of the large intestine: current understanding of diagnosis, pathogenesis, and clinical management J Gastroenterol 2013 48 287 302 23208018 28 Rosenberg DW Yang S Pleau DC Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans Cancer Res 2007 67 3551 3554 17440063 29 Spring KJ Zhao ZZ Karamatic R High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy Gastroenterology 2006 131 1400 1407 17101316 30 Huang CS Farraye FA Yang S O'Brien MJ The clinical significance of serrated polyps Am J Gastroenterol 2011 106 229 240 21045813 31 Arnold CA Montgomery E Iacobuzio-Donahue CA The serrated pathway of neoplasia: new insights into an evolving concept Diagn Histopathol 2011 17 367 375 32 Torlakovic E Snover DC Serrated adenomatous polyposis in humans Gastroenterology 1996 110 748 755 8608884 33 Vieth M Quirke P Lambert R von Karsa L Risio M Annex to Quirke et al. Quality assurance in pathology in colorectal cancer screening and diagnosis: annotations of colorectal lesions Virchows Arch 2011 458 21 30 21061132 34 East JE Atkin WS Bateman AC British Society of Gastroenterology position statement on serrated polyps in the colon and rectum Gut 2017 66 1181 1196 28450390 35 Kahi CJ Li X Eckert GJ Rex DK High colonoscopic prevalence of proximal colon serrated polyps in average-risk men and women Gastrointest Endosc 2012 75 515 520 22018551 36 Hetzel JT Huang CS Coukos JA Variation in the detection of serrated polyps in an average risk colorectal cancer screening cohort Am J Gastroenterol 2010 105 2656 2664 20717107 37 Abdeljawad K Vemulapalli KC Kahi CJ Cummings OW Snover DC Rex DK Sessile serrated polyp prevalence determined by a colonoscopist with a high lesion detection rate and an experienced pathologist Gastrointest Endosc 2015 81 517 524 24998465 38 Bouwens MW van Herwaarden YJ Winkens B Endoscopic characterization of sessile serrated adenomas/polyps with and without dysplasia Endoscopy 2014 46 225 235 24573732 39 Chung SM Chen YT Panczykowski A Schamberg N Klimstra DS Yantiss RK Serrated polyps with “intermediate features” of sessile serrated polyp and microvesicular hyperplastic polyp: a practical approach to the classification of nondysplastic serrated polyps Am J Surg Pathol 2008 32 407 412 18300810 40 Wiland HO 4th Shadrach B Allende D Morphologic and molecular characterization of traditional serrated adenomas of the distal colon and rectum Am J Surg Pathol 2014 38 1290 1297 25127095 41 Jaramillo E Tamura S Mitomi H Endoscopic appearance of serrated adenomas in the colon Endoscopy 2005 37 254 260 15731942 42 Torlakovic EE Gomez JD Driman DK Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA) Am J Surg Pathol 2008 32 21 29 18162766 43 Yantiss RK Oh KY Chen YT Redston M Odze RD Filiform serrated adenomas: a clinicopathologic and immunophenotypic study of 18 cases Am J Surg Pathol 2007 31 1238 1245 17667549 44 Ha SY Lee SM Lee EJ Filiform serrated adenoma is an unusual, less aggressive variant of traditional serrated adenoma Pathology 2012 44 18 23 22157687 45 Pino MS Chung DC The chromosomal instability pathway in colon cancer Gastroenterology 2010 138 2059 2072 20420946 46 Samowitz WS Albertsen H Herrick J Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer Gastroenterology 2005 129 837 845 16143123 47 Hawkins N Norrie M Cheong K CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability Gastroenterology 2002 122 1376 1387 11984524 48 Yang S Farraye FA Mack C Posnik O O'Brien MJ BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status Am J Surg Pathol 2004 28 1452 1459 15489648 49 Chan AO Issa JP Morris JS Hamilton SR Rashid A Concordant CpG island methylation in hyperplastic polyposis Am J Pathol 2002 160 529 536 11839573 50 Wynter CV Walsh MD Higuchi T Leggett BA Young J Jass JR Methylation patterns define two types of hyperplastic polyp associated with colorectal cancer Gut 2004 53 573 580 15016754 51 Minoo P Baker K Goswami R Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis Gut 2006 55 1467 1474 16469793 52 Shima K Morikawa T Yamauchi M TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers PLoS One 2011 6 e25062 21949851 53 Edelstein DL Axilbund JE Hylind LM Serrated polyposis: rapid and relentless development of colorectal neoplasia Gut 2013 62 404 408 22490521 54 Bettington M Walker N Rosty C Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma Gut 2017 66 97 106 26475632 55 Burnett-Hartman AN Passarelli MN Adams SV Differences in epidemiologic risk factors for colorectal adenomas and serrated polyps by lesion severity and anatomical site Am J Epidemiol 2013 177 625 637 23459948 56 Kambara T Simms LA Whitehall VL BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum Gut 2004 53 1137 1144 15247181 57 Campisi J Suppressing cancer: the importance of being senescent Science 2005 309 886 887 16081723 58 Collado M Serrano M The power and the promise of oncogene-induced senescence markers Nat Rev Cancer 2006 6 472 476 16723993 59 Serrano M Lin AW McCurrach ME Beach D Lowe SW Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a Cell 1997 88 593 602 9054499 60 Chen Z Trotman LC Shaffer D Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis Nature 2005 436 725 730 16079851 61 Suzuki H Igarashi S Nojima M IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype Carcinogenesis 2010 31 342 349 19638426 62 Wu JM Montgomery EA Iacobuzio-Donahue CA Frequent beta-catenin nuclear labeling in sessile serrated polyps of the colorectum with neoplastic potential Am J Clin Pathol 2008 129 416 423 18285264 63 Whitehall VL Walsh MD Young J Leggett BA Jass JR Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability Cancer Res 2001 61 827 830 11221863 64 Ogino S Kawasaki T Ogawa A Kirkner GJ Loda M Fuchs CS TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer Hum Pathol 2007 38 614 620 17270239 65 Teriaky A Driman DK Chande N Outcomes of a 5-year follow-up of patients with sessile serrated adenomas Scand J Gastroenterol 2012 47 178 183 22229626 66 Kashida H Ikehara N Hamatani S Kudo SE Kudo M Endoscopic characteristics of colorectal serrated lesions Hepatogastroenterology 2011 58 1163 1167 21937375 67 Williams AR Balasooriya BA Day DW Polyps and cancer of the large bowel: a necropsy study in Liverpool Gut 1982 23 835 842 7117903 68 Su MY Hsu CM Ho YP Chen PC Lin CJ Chiu CT Comparative study of conventional colonoscopy, chromoendoscopy, and narrow-band imaging systems in differential diagnosis of neoplastic and nonneoplastic colonic polyps Am J Gastroenterol 2006 101 2711 2716 17227517 69 Oka S Tanaka S Hiyama T Clinicopathologic and endoscopic features of colorectal serrated adenoma: differences between polypoid and superficial types Gastrointest Endosc 2004 59 213 219 14745394 70 Tadepalli US Feihel D Miller KM A morphologic analysis of sessile serrated polyps observed during routine colonoscopy (with video) Gastrointest Endosc 2011 74 1360 1368 22018553 71 Rustagi T Rangasamy P Myers M Sessile serrated adenomas in the proximal colon are likely to be flat, large and occur in smokers World J Gastroenterol 2013 19 5271 5277 23983429 72 Hazewinkel Y López-Cerón M East JE Endoscopic features of sessile serrated adenomas: validation by international experts using high-resolution white-light endoscopy and narrow-band imaging Gastrointest Endosc 2013 77 916 924 23433877 73 Buda A De Bona M Dotti I Prevalence of different subtypes of serrated polyps and risk of synchronous advanced colorectal neoplasia in average-risk population undergoing first-time colonoscopy Clin Transl Gastroenterol 2012 3 e6 23238028 74 Kim MJ Lee EJ Suh JP Traditional serrated adenoma of the colorectum: clinicopathologic implications and endoscopic findings of the precursor lesions Am J Clin Pathol 2013 140 898 911 24225759 75 Higuchi T Sugihara K Jass JR Demographic and pathological characteristics of serrated polyps of colorectum Histopathology 2005 47 32 40 15982321 76 IJspeert JE Bastiaansen BA van Leerdam ME Development and validation of the WASP classification system for optical diagnosis of adenomas, hyperplastic polyps and sessile serrated adenomas/polyps Gut 2016 65 963 970 25753029 77 Leonard DF Dozois EJ Smyrk TC Endoscopic and surgical management of serrated colonic polyps Br J Surg 2011 98 1685 1694 22034178 78 Lieberman DA Rex DK Winawer SJ Giardiello FM Johnson DA Levin TR Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer Gastroenterology 2012 143 844 857 22763141 79 Hassan C Quintero E Dumonceau JM Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline Endoscopy 2013 45 842 851 24030244 80 Yang DH Hong SN Kim YH Korean guidelines for post-polypectomy colonoscopic surveillance Intest Res 2012 10 89 109